What is the elimination half‑life of Xarelto (rivaroxaban) in healthy adults, and how is it affected in older patients or those with impaired renal function?

Xarelto Half-Life

The elimination half-life of Xarelto (rivaroxaban) is 5–9 hours in healthy young adults and increases to 11–13 hours in elderly patients 1, 2, 3, 4.

Half-Life by Patient Population

Healthy Young Adults

• Terminal half-life: 5–9 hours 2, 3
• Steady-state concentrations achieved within 2–3 days 2

Elderly Patients

• Terminal half-life: 11–13 hours 1, 3, 4
• This prolongation reflects age-related changes in drug clearance
• The pharmacokinetics are minimally influenced by age overall, but the half-life extension is clinically relevant 4

Effect of Renal Impairment

Renal function significantly impacts rivaroxaban elimination because 35% of the absorbed dose is cleared renally 1. The half-life progressively increases with worsening kidney function:

Mild Renal Impairment (CrCl 50–79 mL/min)

• AUC increases 1.44-fold compared to healthy controls 5
• Moderate increase in drug exposure

Moderate Renal Impairment (CrCl 30–49 mL/min)

• AUC increases 1.52-fold 5
• Factor Xa inhibition increases 1.86-fold 5

Severe Renal Impairment (CrCl 15–29 mL/min)

• AUC increases 1.64-fold 5
• Factor Xa inhibition increases 2.0-fold 5
• Rivaroxaban is approved in Europe for use in this population with reduced dosing 1

Hemodialysis Patients

• Mean terminal elimination half-life: 8.6 hours after a single 10 mg dose 6
• Rivaroxaban is NOT removed by dialysis 6
• No accumulation occurs with daily dosing 6
• Mean trough concentration after multiple 10 mg daily doses: 20.2 μg/L 6

Clinical Implications

The dual elimination pathway (65% non-renal/35% renal clearance) 1 means that even in severe renal impairment, the increase in drug exposure is moderate and predictable. The influence of renal function on rivaroxaban clearance plateaus at moderate-to-severe impairment, with comparable increases in exposure among patients with moderate renal impairment, severe renal impairment, and end-stage renal disease 5, 7.

Key Pharmacokinetic Parameters

• Time to peak plasma concentration: Just under 2 hours after oral administration 2
• Plasma protein binding: 95% 1
• Bioavailability: 80–100% for 15–20 mg doses when taken with food 1, 2

Important caveat: The 15 mg and 20 mg doses must be taken with food (preferably the largest meal) to ensure optimal bioavailability 1, 2.